BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30453925)

  • 1. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W
    BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
    Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
    Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
    Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
    Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of transcatheter arterial chemoembolization combined with either
    Li Y; Li H; Hu H; Yuan H; Zhao Y
    J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
    Ouyang T; Cao Y; Chen L; Zheng C
    Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma.
    Liu J; Xie S; Duan X; Chen J; Zhou X; Li Y; Li Z; Han X
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):69-76. PubMed ID: 31813003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.
    Lu W; Jin XL; Yang C; Du P; Jiang FQ; Ma JP; Yang J; Xie P; Zhang Z
    Cancer Biol Ther; 2017 Jun; 18(6):433-438. PubMed ID: 28548587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
    J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
    Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
    Wang H; Liu D; Wang C; Yu S; Jin G; Wang C; Zhang B; Zhang D; Shao D
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101869. PubMed ID: 35108656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
    Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
    Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
    Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients: Efficacy and safety.
    Liu S; Zhao G; Yu G; Guo N; Zhang Y; Li Q; Wang Z
    J Cancer Res Ther; 2020 Sep; 16(5):1165-1170. PubMed ID: 33004765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
    Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
    Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.